<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25048">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893814</url>
  </required_header>
  <id_info>
    <org_study_id>PAB/029911</org_study_id>
    <nct_id>NCT01893814</nct_id>
  </id_info>
  <brief_title>Benefit and Tolerability of a Probiotic Product in Infants With Abdominal Discomfort</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probi AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probi AB</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate benefit and tolerability of a probiotic product in infants with abdominal
      discomfort.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of abdominal discomfort as assessed by comparison of crying time</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Abdominal Discomfort</condition>
  <arm_group>
    <arm_group_label>Probiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <arm_group_label>Probiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female singleton

          -  ≥ 2 weeks and ≤ 12 weeks of age

          -  Exclusively breastfed at screening

          -  Abdominal discomfort (infant colic) in the week prior to enrollment, according to the
             statement of the parent(s) and/or guardian(s)

          -  Episodes of fussy crying that lasted at least 3 hours a day for at least 3 days in
             the 7 days prior to enrollment, according to the statement of the parent(s) and/or
             guardian(s)

          -  Voluntary, written informed consent of the parent(s) and/or guardian(s) to
             participate in the study

          -  Born at full term (37-42 after last menstruation period)

          -  Birth weight: 2500 - 4500 g

          -  Weight-for-age ≥ 3th and ≤ 97th percentile according to WHO growth tables / charts

          -  Apparently healthy at birth (Apgar ≥ 8) and at screening visit

          -  No major complications during pregnancy or at birth

          -  Mother 19-45 years of age at childbirth

          -  Ability of parent(s) and/or guardian(s) to attend visits, interviews and willingness
             to fill out questionnaires

        Exclusion Criteria:

          -  Intolerance to investigational product/its ingredients

          -  Severe medical condition or illness, congenital abnormality

          -  Gastrointestinal disorders (e.g. reflux esophagitis)

          -  Intake of probiotics and/or antibiotics in the week preceding recruitment and during
             the study

          -  Formula feeding at screening/randomisation

          -  Allergy or atopic disease (family history)

          -  Participation in another study

          -  Mother's health condition that may interfere with her ability to take care of her
             infant

          -  Mother affected by hepatitis B, HIV or Guillain-Barré Syndrom

          -  Use of antibiotics by the mother in the week
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Loui, Dr Med</last_name>
    <phone>+49 30 450 566463</phone>
    <email>andrea.loui@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Virchow Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Loui, Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 2, 2013</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
